Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial

Gideon Koren, Shannon Clark, Gary Hankins, Steve N. Caritis, Jason G. Umans, Menachem Miodovnik, Donald R. Mattison, Ilan Matok

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting up to 80% of expecting mothers. In April 2013 the FDA approved the delayed release combination of doxylamine succinate and -pyridoxine hydrochloride (Diclegis®) for NVP, following a phase 3 randomized trial in pregnant women. The fetal safety of this medication has been proven by numerous studies. However, because it is the only FDA-approved medication for NVP that is likely to be used by a large number of pregnant women, its maternal safety is an important public health question. The Objective is to evaluate the maternal safety of doxylamine succinate -pyridoxine hydrochloride delayed-release preparation (Diclegis® as compared to placebo. Methods: We randomized women suffering from NVP to receive Diclegis® (n = 131) or placebo (n = 125) for 14 days at doses ranging from 2-4 tablets a day, based on a pre-specified titration protocol response to symptoms. Adverse events were collected through patient diaries, clinical examination and laboratory testing. Results: Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement. Conclusions: Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy. Trial Registration: Clinical Trial Registration No: NCT00614445.

Original languageEnglish (US)
Article number59
JournalBMC Pregnancy and Childbirth
Volume15
Issue number1
DOIs
StatePublished - Mar 18 2015

Fingerprint

Doxylamine
Pyridoxine
Nausea
Vomiting
Randomized Controlled Trials
Placebos
Mothers
Safety
Pregnancy
Pregnant Women
Tablets
dicyclomine, doxylamine, pyridoxine drug combination
Public Health
Clinical Trials
Depression

Keywords

  • Diclegis
  • Doxylamine
  • Nausea and vomiting of pregnancy
  • Pyridoxine
  • Safety
  • Toxicology

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. / Koren, Gideon; Clark, Shannon; Hankins, Gary; Caritis, Steve N.; Umans, Jason G.; Miodovnik, Menachem; Mattison, Donald R.; Matok, Ilan.

In: BMC Pregnancy and Childbirth, Vol. 15, No. 1, 59, 18.03.2015.

Research output: Contribution to journalArticle

Koren, Gideon ; Clark, Shannon ; Hankins, Gary ; Caritis, Steve N. ; Umans, Jason G. ; Miodovnik, Menachem ; Mattison, Donald R. ; Matok, Ilan. / Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. In: BMC Pregnancy and Childbirth. 2015 ; Vol. 15, No. 1.
@article{3eaf3bedd7b44a639969ffcdad5e1042,
title = "Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial",
abstract = "Background: Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting up to 80{\%} of expecting mothers. In April 2013 the FDA approved the delayed release combination of doxylamine succinate and -pyridoxine hydrochloride (Diclegis{\circledR}) for NVP, following a phase 3 randomized trial in pregnant women. The fetal safety of this medication has been proven by numerous studies. However, because it is the only FDA-approved medication for NVP that is likely to be used by a large number of pregnant women, its maternal safety is an important public health question. The Objective is to evaluate the maternal safety of doxylamine succinate -pyridoxine hydrochloride delayed-release preparation (Diclegis{\circledR} as compared to placebo. Methods: We randomized women suffering from NVP to receive Diclegis{\circledR} (n = 131) or placebo (n = 125) for 14 days at doses ranging from 2-4 tablets a day, based on a pre-specified titration protocol response to symptoms. Adverse events were collected through patient diaries, clinical examination and laboratory testing. Results: Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement. Conclusions: Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy. Trial Registration: Clinical Trial Registration No: NCT00614445.",
keywords = "Diclegis, Doxylamine, Nausea and vomiting of pregnancy, Pyridoxine, Safety, Toxicology",
author = "Gideon Koren and Shannon Clark and Gary Hankins and Caritis, {Steve N.} and Umans, {Jason G.} and Menachem Miodovnik and Mattison, {Donald R.} and Ilan Matok",
year = "2015",
month = "3",
day = "18",
doi = "10.1186/s12884-015-0488-1",
language = "English (US)",
volume = "15",
journal = "BMC Pregnancy and Childbirth",
issn = "1471-2393",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial

AU - Koren, Gideon

AU - Clark, Shannon

AU - Hankins, Gary

AU - Caritis, Steve N.

AU - Umans, Jason G.

AU - Miodovnik, Menachem

AU - Mattison, Donald R.

AU - Matok, Ilan

PY - 2015/3/18

Y1 - 2015/3/18

N2 - Background: Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting up to 80% of expecting mothers. In April 2013 the FDA approved the delayed release combination of doxylamine succinate and -pyridoxine hydrochloride (Diclegis®) for NVP, following a phase 3 randomized trial in pregnant women. The fetal safety of this medication has been proven by numerous studies. However, because it is the only FDA-approved medication for NVP that is likely to be used by a large number of pregnant women, its maternal safety is an important public health question. The Objective is to evaluate the maternal safety of doxylamine succinate -pyridoxine hydrochloride delayed-release preparation (Diclegis® as compared to placebo. Methods: We randomized women suffering from NVP to receive Diclegis® (n = 131) or placebo (n = 125) for 14 days at doses ranging from 2-4 tablets a day, based on a pre-specified titration protocol response to symptoms. Adverse events were collected through patient diaries, clinical examination and laboratory testing. Results: Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement. Conclusions: Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy. Trial Registration: Clinical Trial Registration No: NCT00614445.

AB - Background: Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting up to 80% of expecting mothers. In April 2013 the FDA approved the delayed release combination of doxylamine succinate and -pyridoxine hydrochloride (Diclegis®) for NVP, following a phase 3 randomized trial in pregnant women. The fetal safety of this medication has been proven by numerous studies. However, because it is the only FDA-approved medication for NVP that is likely to be used by a large number of pregnant women, its maternal safety is an important public health question. The Objective is to evaluate the maternal safety of doxylamine succinate -pyridoxine hydrochloride delayed-release preparation (Diclegis® as compared to placebo. Methods: We randomized women suffering from NVP to receive Diclegis® (n = 131) or placebo (n = 125) for 14 days at doses ranging from 2-4 tablets a day, based on a pre-specified titration protocol response to symptoms. Adverse events were collected through patient diaries, clinical examination and laboratory testing. Results: Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement. Conclusions: Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy. Trial Registration: Clinical Trial Registration No: NCT00614445.

KW - Diclegis

KW - Doxylamine

KW - Nausea and vomiting of pregnancy

KW - Pyridoxine

KW - Safety

KW - Toxicology

UR - http://www.scopus.com/inward/record.url?scp=84926665885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926665885&partnerID=8YFLogxK

U2 - 10.1186/s12884-015-0488-1

DO - 10.1186/s12884-015-0488-1

M3 - Article

VL - 15

JO - BMC Pregnancy and Childbirth

JF - BMC Pregnancy and Childbirth

SN - 1471-2393

IS - 1

M1 - 59

ER -